Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

LivaNova PLC - Ordinary Shares (NQ:LIVN)

69.77 +3.51 (+5.30%)
Streaming Delayed Price Updated: 11:07 AM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 294,038
Open 67.38
Bid (Size) 69.69 (300)
Ask (Size) 69.84 (100)
Prev. Close 66.26
Today's Range 66.80 - 69.94
52wk Range 35.00 - 71.92
Shares Outstanding 49,023,767
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
LivaNova (LIVN) Q1 2025 Earnings Transcript ↗
LivaNova (LIVN) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
LivaNova (LIVN) Q2 2025 Earnings Transcript ↗
LivaNova (LIVN) Q2 2025 Earnings Transcript 
Via The Motley Fool
Topics Supply Chain

Performance

YTD
+15.1%
+15.1%
1 Month
+9.9%
+9.9%
3 Month
+6.6%
+6.6%
6 Month
+37.3%
+37.3%
1 Year
+98.4%
+98.4%

More News

Read More
News headline image
LivaNova (LIVN) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
Topics World Trade
LivaNova PLC (NASDAQ:LIVN) Beats Q1 Estimates, Lifts Full-Year Guidance ↗
Via Chartmill
LivaNova (NASDAQ:LIVN) Beats Q4 Estimates, Provides Steady 2026 Outlook ↗
Via Chartmill
News headline image
LivaNova (LIVN) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
From LivaNova PLC
Via Business Wire
News headline image
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
Earnings Scheduled For November 5, 2025 ↗
Via Benzinga
News headline image
LivaNova to Announce First-Quarter 2026 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova (LIVN) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at J.P. Morgan Healthcare Conference in January
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Piper Sandler Healthcare Conference in December
From LivaNova PLC
Via Business Wire
News headline image
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
From LivaNova PLC
Via Business Wire
News headline image
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
From LivaNova PLC
Via Business Wire
News headline image
LivaNova PLC (NASDAQ:LIVN) Beats Q3 2025 Estimates and Raises Full-Year Guidance ↗
Via Chartmill
News headline image
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
From LivaNova PLC
Via Business Wire
News headline image
LivaNova to Present at Wolfe Research Healthcare Conference in November
From LivaNova PLC
Via Business Wire
News headline image
Inspire Medical Systems Soars 3.9% on Groundbreaking Inspire V Clinical Data
Via MarketMinute
News headline image
LivaNova to Announce Third-Quarter 2025 Results
From LivaNova PLC
Via Business Wire

Frequently Asked Questions

Is LivaNova PLC - Ordinary Shares publicly traded?
Yes, LivaNova PLC - Ordinary Shares is publicly traded.
What exchange does LivaNova PLC - Ordinary Shares trade on?
LivaNova PLC - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for LivaNova PLC - Ordinary Shares?
The ticker symbol for LivaNova PLC - Ordinary Shares is LIVN on the Nasdaq Stock Market
What is the current price of LivaNova PLC - Ordinary Shares?
The current price of LivaNova PLC - Ordinary Shares is 69.77
When was LivaNova PLC - Ordinary Shares last traded?
The last trade of LivaNova PLC - Ordinary Shares was at 05/07/26 11:07 AM ET
What is the market capitalization of LivaNova PLC - Ordinary Shares?
The market capitalization of LivaNova PLC - Ordinary Shares is 3.42B
How many shares of LivaNova PLC - Ordinary Shares are outstanding?
LivaNova PLC - Ordinary Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.